How should hospital procurement teams evaluate machine perfusion platforms for the Organ Transplantation Market?

Compare cost per case against measured reductions in delayed graft function and discard, not device list price alone. Service models bundling devices, disposables, and transport staff shift capital spending into operating budgets, which suits mid-volume centers [16]. Read More

What role do donor-derived cell-free DNA tests play in the Organ Transplantation Market?

These blood tests flag graft injury earlier than a creatinine rise, reducing reliance on invasive biopsies. In the Organ Transplantation Market, Medicare coverage for surveillance has made dd-cfDNA a recurring diagnostic revenue stream for vendors such as CareDx [21]. Read More

Which investment risks are specific to xenotransplantation ventures?

Clinical risk centers on porcine virus transmission and long-term graft durability, both unproven in humans. Investors also fund pathogen-free herd facilities that can cost hundreds of millions of dollars before any commercial approval [13]. Read More

How does opt-out consent legislation influence the Organ Transplantation Market?

Opt-out laws rarely lift donation rates on their own. Results depend on family-consent practice, intensive-care capacity, and trained coordinators, which explains why Spain's lead rests on its coordinator network more than its 1979 statute [7]. Read More

What should new entrants know about regulatory pathways for preservation devices?

Preservation devices in the Organ Transplantation Market typically need U.S. premarket approval backed by clinical trials, often taking three to five years. Europe's Medical Device Regulation has also lengthened certification, so entrants usually run EU and U.S. submissions in parallel [17]. Read More

Why are organ procurement organizations investing in dedicated aviation logistics?

Commercial flight delays cause measurable organ loss, especially for hearts and lungs with short ischemic windows. Dedicated aircraft give procurement teams control over transport timing and chain-of-custody records [1]. Read More

How do transplant tourism rules affect cross-border demand in the Organ Transplantation Market?

The Declaration of Istanbul and national anti-trafficking laws restrict commercial transplant travel. Countries such as India now require ethics committee approval for foreign donor-recipient pairs, which slows but legitimizes medical-travel volumes [18]. Read More

Organ Transplantation Market (2026 - 2035)

ID: MRFR/Pharma/0410-HCR 80 Pages Rahul Gotadki Last Updated: October 12, 2026

Organ Transplantation Market Research Report By Type Of Organ (Heart, Kidney, Others), By Products (Organ Preservation Solutions, Transplant Diagnostics, Tissue Products), By Type Of Transplant (Autograft, Allograft And Others), By Treatment (Analgesic, Immunosuppressant And Other), By End Users (Hospitals, Transplant Centers And Other) - Forecast Till 2035

Organ Transplantation Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)9.35%

2025 Market SizeUSD 7.84 Billion

2035 Market SizeUSD 19.11 Billion

Key Players

Astellas Pharma

Novartis

TransMedics Group

Sanofi

Veloxis Pharmaceuticals

CareDx

Trends

Rising End-Stage Organ Disease Burden
Machine Perfusion Adoption
Opt-Out Consent and DCD Expansion

Opportunities

Emerging-Market Deceased-Donor Programs
Data Platforms and AI-Driven Matching
Organ-Logistics-as-a-Service Models

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary | |
2 Key Report Takeaways | |
1. 2.1 By Organ Type | |
2. 2.2 By Donor Type | |
3. 2.3 By Type of Transplant | |
4. 2.4 By Organ-Preservation Technique | |
5. 2.5 By Product Type | |
6. 2.6 By End User | |
7. 2.7 By Region | |
3 Market Size and Forecast (2021–2035) | |
4 Driver Impact Analysis | |
1. 4.1 Rising End-Stage Organ Disease Burden | |
2. 4.2 Machine Perfusion Adoption | |
3. 4.3 U.S. Payment and Allocation Reform | |
4. 4.4 Opt-Out Consent and DCD Expansion | |
5. 4.5 Living-Donor Financial Support | |
6. 4.6 Next-Generation Immunosuppression and Diagnostics | |
5 Restraints Impact Analysis | |
1. 5.1 Donor Organ Shortage and Discard | |
2. 5.2 High Procedure and Lifetime Costs | |
3. 5.3 Immunosuppression Toxicity and Nonadherence | |
4. 5.4 Ethical and Regulatory Constraints | |
5. 5.5 Workforce and Infrastructure Gaps | |
6 Opportunities | |
1. 6.1 Emerging-Market Deceased-Donor Programs | |
2. 6.2 Data Platforms and AI-Driven Matching | |
3. 6.3 Organ-Logistics-as-a-Service Models | |
4. 6.4 Xenotransplantation and Bioengineered Organs | |
5. 6.5 Biosimilar and Precision Immunosuppression | |
7 Regional Market Share and Country-Level Analysis | |
1. 7.1 North America | | |
  1. 7.1.1 US | | |
  2. 7.1.2 Canada | | |
  3. 7.1.3 Mexico | |
2. 7.2 Europe | | |
  1. 7.2.1 Germany | | |
  2. 7.2.2 UK | | |
  3. 7.2.3 France | | |
  4. 7.2.4 Italy | | |
  5. 7.2.5 Spain | | |
  6. 7.2.6 Nordic Countries | | |
  7. 7.2.7 Russia | | |
  8. 7.2.8 Rest of Europe | |
3. 7.3 Asia-Pacific | | |
  1. 7.3.1 China | | |
  2. 7.3.2 India | | |
  3. 7.3.3 Japan | | |
  4. 7.3.4 South Korea | | |
  5. 7.3.5 ASEAN | | |
  6. 7.3.6 Rest of Asia-Pacific | |
4. 7.4 South America | | |
  1. 7.4.1 Brazil | | |
  2. 7.4.2 Argentina | | |
  3. 7.4.3 Rest of South America | |
5. 7.5 Middle East & Africa | | |
  1. 7.5.1 Saudi Arabia | | |
  2. 7.5.2 UAE | | |
  3. 7.5.3 South Africa | | |
  4. 7.5.4 Egypt | | |
  5. 7.5.5 Rest of MEA | |
8 Future Outlook (2026–2035) | |
1. 8.1 AI-Assisted Allocation and Acceptance | |
2. 8.2 Perfusion-Centered Organ Logistics | |
3. 8.3 Xenotransplant and Regenerative Pipeline | |
4. 8.4 Value-Based Payment and Outcome Transparency | |
9 Segmentation Analysis | |
1. 9.1 By Organ Type | | |
  1. 9.1.1 Kidney | | |
  2. 9.1.2 Liver | | |
  3. 9.1.3 Heart | | |
  4. 9.1.4 Lung | | |
  5. 9.1.5 Pancreas | | |
  6. 9.1.6 Intestine | | |
  7. 9.1.7 Other Organs | |
2. 9.2 By Donor Type | | |
  1. 9.2.1 Deceased Donor | | |
  2. 9.2.2 Living Donor | |
3. 9.3 By Type of Transplant | | |
  1. 9.3.1 Allogeneic | | |
  2. 9.3.2 Autologous | | |
  3. 9.3.3 Xenotransplantation & Composite Tissue Allografts | |
4. 9.4 By Organ-Preservation Technique | | |
  1. 9.4.1 Static Cold Storage | | |
  2. 9.4.2 Hypothermic Machine Perfusion | | |
  3. 9.4.3 Normothermic Machine Perfusion | | |
  4. 9.4.4 Other Novel Methods | |
5. 9.5 By Product Type | | |
  1. 9.5.1 Immunosuppressants | | |
  2. 9.5.2 Organ Preservation Solutions & Devices | | |
  3. 9.5.3 Tissue Products | | |
  4. 9.5.4 Digital Therapeutics & Tele-transplant Platforms | | |
  5. 9.5.5 Transplant Diagnostics | |
6. 9.6 By End User | | |
  1. 9.6.1 Hospitals | | |
  2. 9.6.2 Transplant Centers | | |
  3. 9.6.3 Ambulatory Clinics & Same-Day Surgical Centers | | |
  4. 9.6.4 Research & Academic Institutes | |
10 Competitive Landscape | |
1. 10.1 Market Concentration Analysis | |
2. 10.2 Competitive Benchmarking Matrix | |
11 Recent News & Developments | |
12 Report Scope and Methodology | |
13 Detailed Sources and Citations | |
14 Frequently Asked Questions (FAQs) | | LIST OF TABLES | |
TABLE 1 Global Market Snapshot, 2025–2035 | |
TABLE 2 Global Market Size & Forecast, by Revenue (USD Billion), 2021–2035 | |
TABLE 3 Driver Impact Analysis | |
TABLE 4 Restraints Impact Analysis | |
TABLE 5 Regional Market Summary, 2025 | |
TABLE 6 North America Market, by Country, 2025 | |
TABLE 7 Europe Market, by Country, 2025 | |
TABLE 8 Asia-Pacific Market, by Country, 2025 | |
TABLE 9 South America Market, by Country, 2025 | |
TABLE 10 Middle East & Africa Market, by Country, 2025 | |
TABLE 11 Global Market, by Organ Type, 2025 | |
TABLE 12 Global Market, by Donor Type, 2025 | |
TABLE 13 Global Market, by Type of Transplant, 2025 | |
TABLE 14 Global Market, by Organ-Preservation Technique, 2025 | |
TABLE 15 Global Market, by Product Type, 2025 | |
TABLE 16 Global Market, by End User, 2025 | |
TABLE 17 Competitive Benchmarking Matrix, 2025 | |
TABLE 18 Report Scope and Methodology | |
TABLE 19 Detailed Sources and Citations | | LIST OF FIGURES | |
FIGURE 1 Market Dynamics Overview (Drivers, Restraints, Opportunities) | |
FIGURE 2 Industry Value Chain Analysis | |
FIGURE 3 Porter's Five Forces Analysis | |
FIGURE 4 Global Market Size Trend, 2021–2035 (USD Billion) | |
FIGURE 5 Market Share by Organ Type, 2025 | |
FIGURE 6 Market Share by Donor Type, 2025 | |
FIGURE 7 Market Share by Type of Transplant, 2025 | |
FIGURE 8 Market Share by Organ-Preservation Technique, 2025 | |
FIGURE 9 Market Share by Product Type, 2025 | |
FIGURE 10 Market Share by End User, 2025 | |
FIGURE 11 Regional Market Share, 2025 | |
FIGURE 12 Regional Growth Comparison, 2026–2035 | |
FIGURE 13 Competitive Landscape Positioning Map, 2025

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Organ Type	Kidney, Liver, Heart, Lung, Pancreas, Other Organs	Kidney (58.2% share)	Lung (9.72% CAGR)
By Donor Type	Deceased Donor, Living Donor	Deceased Donor (64.8% share)	Living Donor (9.86% CAGR)
By Type of Transplant	Allogeneic, Autologous, Xenotransplantation & Composite Tissue Allografts	Allogeneic (78.6% share)	Xenotransplantation & Composite Tissue Allografts (13.8% CAGR)
By Organ-Preservation Technique	Static Cold Storage, Hypothermic Machine Perfusion, Normothermic Machine Perfusion	Static Cold Storage (66.9% share)	Normothermic Machine Perfusion (12.4% CAGR)
By Product Type	Immunosuppressants, Organ Preservation Solutions & Devices, Tissue Products, Digital Therapeutics & Tele-transplant Platforms	Immunosuppressants (47.9% share)	Digital Therapeutics & Tele-transplant Platforms (19.4% CAGR)
By End User	Hospitals, Transplant Centers, Ambulatory Clinics & Same-Day Surgical Centers, Research & Academic Institutes	Hospitals (53.4% share)	Ambulatory Clinics & Same-Day Surgical Centers (13.1% CAGR)
By Region	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America (41.5% share)	Asia-Pacific (11.4% CAGR)

Market Segmentation Overview

By Organ Type

Sub-Segment	Key Trend
Kidney	Living-donor and paired-exchange growth
Liver	Perfusion enables use of marginal grafts
Heart	DCD heart recovery with portable perfusion
Lung	Ex vivo lung perfusion expands donor pool
Pancreas	Simultaneous pancreas-kidney procedures
Other Organs	Pediatric intestinal transplants

Kidney leads organ volume because end-stage renal disease generates the largest waiting list and living donation is routine for this organ. Lung grows fastest since ex vivo perfusion lets centers assess and recondition lungs once declined for poor oxygenation. Liver remains the clear second, gaining from normothermic perfusion of steatotic grafts.

By Donor Type

Sub-Segment	Key Trend
Deceased Donor	DCD protocols widen eligibility
Living Donor	Lost-wage reimbursement and exchange chains

Deceased Donor grafts dominate because procurement organizations and DCD protocols supply most livers, hearts, and lungs. Living Donor activity grows faster as programs reimburse travel and lost wages, while paired exchange turns incompatible pairs into transplant chains. Asian centers add momentum through living-donor liver surgery for children.

By Type of Transplant

Sub-Segment	Key Trend
Allogeneic	Machine-learning HLA matching
Autologous	Confined to hematopoietic and tissue use
Xenotransplantation & Composite Tissue Allografts	Gene-edited pig kidney trials

Allogeneic transplants lead because human donor organs remain the only approved option for solid-organ replacement, and improved HLA matching keeps rejection falling. Xenotransplantation & Composite Tissue Allografts grow fastest from a small base, driven by FDA-cleared pig kidney trials. Autologous procedures stay a niche limited to hematopoietic and tissue applications.

By Organ-Preservation Technique

Sub-Segment	Key Trend
Static Cold Storage	Low-cost default for standard grafts
Hypothermic Machine Perfusion	Randomized evidence for kidneys
Normothermic Machine Perfusion	Viability testing during transport

Static Cold Storage still leads because it is inexpensive and works well for standard-criteria organs. Normothermic Machine Perfusion grows fastest by allowing surgeons to test function and repair grafts before implantation, cutting discard. Hypothermic Machine Perfusion holds a solid middle position, particularly for kidneys in Europe and Australia.

By Product Type

Sub-Segment	Key Trend
Immunosuppressants	Biosimilar entry and extended-release formulations
Organ Preservation Solutions & Devices	Perfusion consumables revenue
Tissue Products	Tissue banking demand
Digital Therapeutics & Tele-transplant Platforms	Adherence apps and remote monitoring

Immunosuppressants lead product revenue because every recipient needs lifelong maintenance therapy, though biosimilars are compressing prices. Digital Therapeutics & Tele-transplant Platforms grow fastest as centers use apps and remote monitoring to curb nonadherence. Organ Preservation Solutions & Devices rise with each perfused case, which carries far higher consumable spend than cold storage.

By End User

Sub-Segment	Key Trend
Hospitals	Complex surgery and intensive care
Transplant Centers	Concentrated high-volume expertise
Ambulatory Clinics & Same-Day Surgical Centers	Same-day donor nephrectomy
Research & Academic Institutes	Perfusion and xenograft trials

Hospitals lead because recipient surgery requires intensive care, infection control, and multidisciplinary teams. Ambulatory Clinics & Same-Day Surgical Centers grow fastest as laparoscopic donor nephrectomy and enhanced-recovery pathways allow discharge within 24 hours. Transplant Centers retain a large share by concentrating surgical volume and advanced preservation suites.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”